Eaton Vance Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Eaton Vance Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$22.8M	Buy	287,557 +31,459	+12%	+$2.65M	0.03%	408
2022 Q2	$19M	Buy	256,098 +146,790	+134%	+$11M	0.03%	469
2022 Q1	$9.82M	Sell	109,308 -70,383	-39%	-$6.5M	0.01%	696
2021 Q4	$20.1M	Buy	179,691 +2,326	+1%	+$281K	0.02%	472
2021 Q3	$22.2M	Buy	177,365 +6,736	+4%	+$867K	0.03%	408
2021 Q2	$23.1M	Sell	170,629 -1,042	-0.6%	-$137K	0.03%	427
2021 Q1	$23.3M	Buy	171,671 +6,451	+4%	+$966K	0.03%	410
2020 Q4	$23.3M	Sell	165,220 -36,184	-18%	-$4.63M	0.04%	391
2020 Q3	$22.4M	Sell	201,404 -8,951	-4%	-$1M	0.04%	341
2020 Q2	$23.5M	Sell	210,355 -13,548	-6%	-$1.33M	0.05%	311
2020 Q1	$17.3M	Buy	223,903 +38,911	+21%	+$3.45M	0.04%	316
2019 Q4	$17.6M	Buy	184,992 +3,138	+2%	+$271K	0.03%	357
2019 Q3	$13.9M	Buy	181,854 +9,281	+5%	+$771K	0.03%	381
2019 Q2	$15.1M	Buy	172,573 +11,536	+7%	+$984K	0.03%	353
2019 Q1	$14.6M	Buy	161,037 +50,111	+45%	+$4.26M	0.03%	340
2018 Q4	$7.96M	Sell	110,926 -6,673	-6%	-$538K	0.02%	419
2018 Q3	$11.3M	Buy	117,599 +17,469	+17%	+$1.69M	0.03%	390
2018 Q2	$9.53M	Sell	100,130 -72,954	-42%	-$6.7M	0.02%	407
2018 Q1	$15.2M	Buy	173,084 +98,720	+133%	+$9.01M	0.02%	431
2017 Q4	$6.31M	Buy	74,364 +38,685	+108%	+$3.24M	0.02%	469
2017 Q3	$3.09M	Buy	35,679 +14,258	+67%	+$1.14M	0.01%	595
2017 Q2	$1.65M	Buy	+21,421	New	+$1.52M	﹤0.01%	712

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Eaton Vance Management's XBI Position: Q3 2022 in Review

Eaton Vance Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 12% in Q3 2022, buying an estimated $2.65M and bringing the position to 287,557 shares worth $22.8M. The position accounts for 0.03% of the portfolio, ranked #408.

Eaton Vance Management first reported a position in XBI in Q2 2017 and has held it in 22 quarters since. The position peaked at $23.5M in Q2 2020. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Eaton Vance Management held 287,557 shares of State Street SPDR S&P Biotech ETF worth $22.8M as of Q3 2022.
Eaton Vance Management bought 31,459 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $2.65M.
State Street SPDR S&P Biotech ETF made up 0.03% of Eaton Vance Management's portfolio in Q3 2022, its #408 holding.
Eaton Vance Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 22 quarters since.
Eaton Vance Management's State Street SPDR S&P Biotech ETF position peaked at $23.5M in Q2 2020.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.